19 results on '"Drekonja D"'
Search Results
2. Research agenda for antibiotic stewardship within the Veterans' Health Administration, 2024-2028.
- Author
-
Livorsi DJ, Branch-Elliman W, Drekonja D, Echevarria KL, Fitzpatrick MA, Goetz MB, Graber CJ, Jones MM, Kelly AA, Madaras-Kelly K, Morgan DJ, Stevens VW, Suda K, Trautner BW, Ward MJ, and Jump RLP
- Published
- 2024
- Full Text
- View/download PDF
3. Engaging patients in antimicrobial stewardship: co-designed educational tool to improve periprocedural care through de-implementation of guideline-discordant antimicrobial use.
- Author
-
Al Lawati H, Shin M, Lamkin R, Thompson T, Epshtein I, Mull H, Basnet Thapa D, Drekonja D, Rodriguez-Barradas MC, Xu TH, Gold H, Elwy AR, Strymish J, and Branch-Elliman W
- Abstract
Effective de-implementation models often include replacement of an ineffective practice with an alternative. We co-developed patient education materials as a replacement strategy for inappropriate post-procedural antibiotics in cardiac device procedures. Lessons learned and developed materials may be used to promote infection prevention in other periprocedural settings., Competing Interests: All authors report no conflicts of interest relevant to this article., (© The Author(s) 2023.)
- Published
- 2023
- Full Text
- View/download PDF
4. Rifampin for Prosthetic Joint Infections: Lessons Learned Over 20 Years at a VA Medical Center.
- Author
-
Cushing S and Drekonja D
- Abstract
Background: The Minneapolis Veterans Affairs Health Care System uses debridement and implant retention (DAIR) combined with oral rifampin and a second antibiotic to treat orthopedic implant infections. However, the success rate of this approach in a veteran population is unknown., Methods: We performed a retrospective analysis of patients who underwent DAIR with a rifampin-containing regimen for an orthopedic implant infection over the past 20 years at the Minneapolis Veterans Affairs Health Care System. The primary outcome was treatment success among participants who were treated with curative intent, defined as planned device retention without ongoing antibiotic use. Secondary outcomes were treatment harms and therapy duration. Treatment success was defined as the absence of recurrent infection or further measures to suppress infection within 1 year of completing antimicrobial therapy., Results: A total of 78 patients (88% male) were included (median age, 65.5 years), with 50 treated with curative intent (primary analysis group). Forty-one participants (82%) in the curative intent group experienced treatment success. The success rate was higher among participants whose implant was < 2 months old vs those whose implant was ≥ 2 months old (93% vs 65%, respectively; P = .02). The 28 participants treated without curative intent had more comorbidities, higher rates of chronic infection, and older implants than those treated with curative intent., Conclusions: Veterans with orthopedic implant infections can be successfully treated with DAIR combined with a rifampin-containing antimicrobial regimen. Success is highest for patients with a recent implant. Debridement and implant retention using regimens that include rifampin is an evidence-based strategy for managing patients with infected prosthetic hardware. Here we report that this approach is feasible in a veteran population, especially with recently implanted prosthetic material., Competing Interests: Author disclosures The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article., (Copyright © 2023 Frontline Medical Communications Inc., Parsippany, NJ, USA.)
- Published
- 2023
- Full Text
- View/download PDF
5. Identification of novel factors associated with inappropriate treatment of asymptomatic bacteriuria in acute and long-term care.
- Author
-
Valentine-King M, Van J, Hines-Munson C, Dillon L, Graber CJ, Patel PK, Drekonja D, Lichtenberger P, Shukla B, Kramer J, Ramsey D, Trautner B, and Grigoryan L
- Abstract
Background: Chart reviews often fall short of determining what drove antibiotic treatment of asymptomatic bacteriuria (ASB). To overcome this shortcoming, we searched providers' free-text for documentation of their decision-making and for misleading signs and symptoms that may trigger unnecessary treatment of ASB., Methods: We reviewed a random sample of 10 positive urine cultures per month, per facility, from patients in acute or long-term care wards at 8 Veterans Affairs facilities. Cultures were classified as urinary tract infection (UTI) or ASB, and as treated or untreated. Charts were searched for 13 potentially misleading symptoms, and free-text documentation of providers' decision-making was classified into 5 categories. We used generalized estimating equations logistic regression to identify factors associated with ASB treatment., Results: One hundred fifty-eight (27.5%) of 575 ASB cases were inappropriately treated with antibiotics. Significant factors associated with inappropriate treatment included: abdominal pain, falls, decreased urine output, urine characteristics, abnormal vital signs, laboratory values, and voiding issues. Providers prescribed an average of 1.4 antimicrobials to patients with ASB, with cephalosporins (41%) and fluoroquinolones (21%) being the most common classes prescribed., Conclusions: Chart reviews of providers' decision-making highlighted new factors associated with inappropriate ASB treatment. These findings can help design antibiotic stewardship interventions for ASB., (Copyright © 2022 Association for Professionals in Infection Control and Epidemiology, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
6. Response to the article by Kwak et al entitled "No increased incidence of Clostridium difficile infection among patients with hidradenitis suppurativa treated with systemic clindamycin".
- Author
-
Greenlund LK, Herzog C, Drekonja D, and Goldfarb N
- Subjects
- Anti-Bacterial Agents adverse effects, Clindamycin adverse effects, Humans, Incidence, Clostridium Infections drug therapy, Clostridium Infections epidemiology, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa epidemiology
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2022
- Full Text
- View/download PDF
7. Promoting de-implementation of inappropriate antimicrobial use in cardiac device procedures by expanding audit and feedback: protocol for hybrid III type effectiveness/implementation quasi-experimental study.
- Author
-
Branch-Elliman W, Lamkin R, Shin M, Mull HJ, Epshtein I, Golenbock S, Schweizer ML, Colborn K, Rove J, Strymish JM, Drekonja D, Rodriguez-Barradas MC, Xu TH, and Elwy AR
- Subjects
- Anti-Bacterial Agents therapeutic use, Feedback, Humans, Inappropriate Prescribing prevention & control, Anti-Infective Agents therapeutic use, Defibrillators, Implantable
- Abstract
Background: Despite a strong evidence base and clinical guidelines specifically recommending against prolonged post-procedural antimicrobial use, studies indicate that the practice is common following cardiac device procedures. Formative evaluations conducted by the study team suggest that inappropriate antimicrobial use may be driven by information silos that drive provider belief that antimicrobials are not harmful, in part due to lack of complete feedback about all types of clinical outcomes. De-implementation is recognized as an important area of research that can lead to reductions in unnecessary, wasteful, or harmful practices, such as excess antimicrobial use following cardiac device procedures; however, investigations into strategies that lead to successful de-implementation are limited. The overarching hypothesis to be tested in this trial is that a bundle of implementation strategies that includes audit and feedback about direct patient harms caused by inappropriate prescribing can lead to successful de-implementation of guideline-discordant care., Methods: We propose a hybrid type III effectiveness-implementation stepped-wedge intervention trial at three high-volume, high-complexity VA medical centers. The main study intervention (an informatics-based, real-time audit-and-feedback tool) was developed based on learning/unlearning theory and formative evaluations and guided by the integrated-Promoting Action on Research Implementation in Health Services (i-PARIHS) Framework. Elements of the bundled and multifaceted implementation strategy to promote appropriate prescribing will include audit-and-feedback reports that include information about antibiotic harms, stakeholder engagement, patient and provider education, identification of local champions, and blended facilitation. The primary study outcome is adoption of evidence-based practice (de-implementation of inappropriate antimicrobial use). Clinical outcomes (cardiac device infections, acute kidney injuries and Clostridioides difficile infections) are secondary. Qualitative interviews will assess relevant implementation outcomes (acceptability, adoption, fidelity, feasibility)., Discussion: De-implementation theory suggests that factors that may have a particularly strong influence on de-implementation include strength of the underlying evidence, the complexity of the intervention, and patient and provider anxiety and fear about changing an established practice. This study will assess whether a multifaceted intervention mapped to identified de-implementation barriers leads to measurable improvements in provision of guideline-concordant antimicrobial use. Findings will improve understanding about factors that impact successful or unsuccessful de-implementation of harmful or wasteful healthcare practices., Trial Registration: ClinicalTrials.gov NCT05020418., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
8. Why N95 Should Be the Standard for All COVID-19 Inpatient Care.
- Author
-
Drekonja D
- Subjects
- Humans, Inpatients, Masks, SARS-CoV-2, Sterilization, COVID-19
- Published
- 2021
- Full Text
- View/download PDF
9. Study Protocol: Seven vs. 14 days treatment for afebrile men with urinary tract infection.
- Author
-
Amundson C, Johnson J, Trautner B, and Drekonja D
- Abstract
The optimal treatment duration for men with urinary tract infection (UTI) is poorly defined. Observational data suggests that shorter-duration therapy may perform as well as longer-duration therapy, but trial data are lacking. We present the protocol and methods for a Department of Veterans Affairs-funded trial of seven vs. 14 days of antimicrobial therapy for afebrile men with UTI, with the primary outcome of symptom resolution 14 days after completing active antimicrobial treatment. An optional sub-study will investigate the effect of treatment duration on the intestinal carriage of antimicrobial-resistant microorganisms. Subjects are enrolled after their UTI is diagnosed and treatment initiated, using a combination of in-person and mail enrollment to maximize participation and minimize resource utilization. This trial will provide high-quality evidence to guide the management of a common infectious disease and potentially limit unnecessary antimicrobial use., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2021 Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
10. Resident Physician Prescribing Variability Demonstrates Need for Antimicrobial Stewardship in Continuity Clinic: A Pilot Study.
- Author
-
Andrews S, Beaudoin A, Rothenberger M, and Drekonja D
- Subjects
- Ambulatory Care Facilities, Anti-Bacterial Agents therapeutic use, Female, Foreign Medical Graduates statistics & numerical data, Humans, Internal Medicine education, Male, Minnesota, Pilot Projects, Practice Patterns, Physicians' statistics & numerical data, United States, United States Department of Veterans Affairs, Antimicrobial Stewardship, Health Knowledge, Attitudes, Practice, Internship and Residency
- Abstract
Background: Inappropriate antimicrobial use is common in the outpatient setting but often goes unaddressed by stewardship education. Residents might benefit from directed stewardship education., Objective: We conducted a needs assessment of resident knowledge, attitudes, and behaviors regarding antibiotic use and stewardship in outpatient continuity clinics., Methods: Internal medicine (IM) residents with continuity clinic at Minneapolis Veterans Affairs Health Care System were eligible. Antimicrobial prescriptions and number of visits were extracted from the Computerized Patient Record System (July 1, 2017-March 31, 2018). Antimicrobial rate (prescriptions per 1000 visits) was calculated for each resident. Results from a resident survey that included demographics, attitudes, and case-based multiple-choice knowledge questions were linked by unique identifier to antimicrobial rate., Results: Prescription and visit data were available for 37 residents. Mean monthly antimicrobial rate was 51 prescriptions per 1000 visits (range 8-239). Surveys were completed by 19 residents (51%). Respondents were 32% female, 32% interns, and 11% international medical graduates. An online resource was most commonly used for prescribing guidance, whereas lectures and small group sessions for residents were rated as the most helpful educational modalities. Many respondents reported being unprepared to perform basic tasks related to antimicrobial stewardship. Median percentage correct was 57% of case-based knowledge questions (interquartile range 50%-71%)., Conclusions: Antimicrobial rates among IM residents at a VA outpatient continuity clinic are low and vary by provider. Residents agree with key antimicrobial stewardship concepts but lack preparation in tasks related to antimicrobial stewardship. Knowledge regarding antimicrobial prescribing was low., Competing Interests: Conflict of interest: The authors declare they have no competing interests., (Accreditation Council for Graduate Medical Education 2020.)
- Published
- 2020
- Full Text
- View/download PDF
11. No Clinical Benefit to Treating Male Urinary Tract Infection Longer Than Seven Days: An Outpatient Database Study.
- Author
-
Germanos GJ, Trautner BW, Zoorob RJ, Salemi JL, Drekonja D, Gupta K, and Grigoryan L
- Abstract
Background: The optimal approach for treating outpatient male urinary tract infections (UTIs) is unclear. We studied the current management of male UTI in private outpatient clinics, and we evaluated antibiotic choice, treatment duration, and the outcome of recurrence of UTI., Methods: Visits for all male patients 18 years of age and older during 2011-2015 with International Classification of Diseases, Ninth Revision, Clinical Modification codes for UTI or associated symptoms were extracted from the EPIC Clarity Database of 2 family medicine, 2 urology, and 1 internal medicine clinics. For eligible visits in which an antibiotic was prescribed, we extracted data on the antibiotic used, treatment duration, recurrent UTI episodes, and patient medical and surgical history., Results: A total of 637 visits were included for 573 unique patients (mean age 53.7 [±16.7 years]). Fluoroquinolones were the most commonly prescribed antibiotics (69.7%), followed by trimethoprim-sulfamethoxazole (21.2%), nitrofurantoin (5.3%), and beta-lactams (3.8%). Antibiotic choice was not associated with UTI recurrence. In the overall cohort, longer treatment duration was not significantly associated with UTI recurrence (odds ratio [OR] = 1.95; 95% confidence interval [CI], 0.91-4.21). Longer treatment was associated with increased recurrence after excluding men with urologic abnormalities, immunocompromising conditions, prostatitis, pyelonephritis, nephrolithiasis, and benign prostatic hyperplasia (OR = 2.62; 95% CI, 1.04-6.61)., Conclusions: Our study adds evidence that men with UTI without evidence of complicating conditions do not need to be treated for longer than 7 days. Shorter duration of treatment was not associated with increased risk of recurrence. Shorter treatment durations for many infections, including UTI, are becoming more attractive to reduce the risk of resistance, adverse events, and costs.
- Published
- 2019
- Full Text
- View/download PDF
12. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America.
- Author
-
Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, Eckert LO, Geerlings SE, Köves B, Hooton TM, Juthani-Mehta M, Knight SL, Saint S, Schaeffer AJ, Trautner B, Wullt B, and Siemieniuk R
- Subjects
- Adult, Aged, Anti-Bacterial Agents therapeutic use, Antimicrobial Stewardship, Bacteriuria diagnosis, Child, Female, Humans, Male, Neutropenia complications, Pregnancy, Prevalence, Transplant Recipients, Urinary Tract Infections drug therapy, Asymptomatic Infections, Bacteriuria drug therapy, Disease Management, Urinary Tract Infections microbiology
- Abstract
Asymptomatic bacteriuria (ASB) is a common finding in many populations, including healthy women and persons with underlying urologic abnormalities. The 2005 guideline from the Infectious Diseases Society of America recommended that ASB should be screened for and treated only in pregnant women or in an individual prior to undergoing invasive urologic procedures. Treatment was not recommended for healthy women; older women or men; or persons with diabetes, indwelling catheters, or spinal cord injury. The guideline did not address children and some adult populations, including patients with neutropenia, solid organ transplants, and nonurologic surgery. In the years since the publication of the guideline, further information relevant to ASB has become available. In addition, antimicrobial treatment of ASB has been recognized as an important contributor to inappropriate antimicrobial use, which promotes emergence of antimicrobial resistance. The current guideline updates the recommendations of the 2005 guideline, includes new recommendations for populations not previously addressed, and, where relevant, addresses the interpretation of nonlocalizing clinical symptoms in populations with a high prevalence of ASB., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
13. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America.
- Author
-
Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, Eckert LO, Geerlings SE, Köves B, Hooton TM, Juthani-Mehta M, Knight SL, Saint S, Schaeffer AJ, Trautner B, Wullt B, and Siemieniuk R
- Subjects
- Adult, Aged, Antimicrobial Stewardship, Bacteriuria diagnosis, Child, Female, Humans, Male, Neutropenia complications, Pregnancy, Prevalence, Transplant Recipients, Urinary Tract Infections drug therapy, Anti-Bacterial Agents therapeutic use, Asymptomatic Infections, Bacteriuria drug therapy, Disease Management, Urinary Tract Infections microbiology
- Abstract
Asymptomatic bacteriuria (ASB) is a common finding in many populations, including healthy women and persons with underlying urologic abnormalities. The 2005 guideline from the Infectious Diseases Society of America recommended that ASB should be screened for and treated only in pregnant women or in an individual prior to undergoing invasive urologic procedures. Treatment was not recommended for healthy women; older women or men; or persons with diabetes, indwelling catheters, or spinal cord injury. The guideline did not address children and some adult populations, including patients with neutropenia, solid organ transplants, and nonurologic surgery. In the years since the publication of the guideline, further information relevant to ASB has become available. In addition, antimicrobial treatment of ASB has been recognized as an important contributor to inappropriate antimicrobial use, which promotes emergence of antimicrobial resistance. The current guideline updates the recommendations of the 2005 guideline, includes new recommendations for populations not previously addressed, and, where relevant, addresses the interpretation of nonlocalizing clinical symptoms in populations with a high prevalence of ASB., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
14. Patient Knowledge and Attitudes About Fecal Microbiota Therapy for Clostridium difficile Infection.
- Author
-
Goodman C, O'Rourke N, Amundson C, and Drekonja D
- Abstract
In a survey of patients with Clostridium difficile infection, physician recommendation seemed to be the largest factor affecting the likelihood of patients considering future fecal microbial therapy., Competing Interests: Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.
- Published
- 2017
15. Further Misanalysis of Urinalysis.
- Author
-
Drekonja D
- Subjects
- Urinalysis
- Published
- 2016
- Full Text
- View/download PDF
16. Rapid access to comprehensive care may explain better outcomes in persons with sepsis with solid organ transplant versus those without solid organ transplant.
- Author
-
Bahr NC, Beaudoin A, and Drekonja D
- Subjects
- Female, Humans, Male, Bacteremia mortality, Transplant Recipients
- Published
- 2015
- Full Text
- View/download PDF
17. Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review.
- Author
-
Drekonja D, Reich J, Gezahegn S, Greer N, Shaukat A, MacDonald R, Rutks I, and Wilt TJ
- Subjects
- Humans, Recurrence, Biological Therapy methods, Clostridioides difficile, Clostridium Infections therapy, Feces microbiology, Microbiota
- Abstract
Background: The role of fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) is not well-known., Purpose: To assess the efficacy, comparative effectiveness, and harms of FMT for CDI., Data Sources: MEDLINE (1980 to January 2015), Cochrane Library, and ClinicalTrials.gov, followed by hand-searching references from systematic reviews and identified studies., Study Selection: Any study of FMT to treat adult patients with CDI; case reports were only used to report harms., Data Extraction: Data were extracted by 1 author and verified by another; 2 authors independently assessed risk of bias and strength of evidence., Data Synthesis: Two randomized, controlled trials (RCTs); 28 case-series studies; and 5 case reports were included. Two RCTs and 21 case-series studies (516 patients receiving FMT) reported using FMT for patients with recurrent CDI. A high proportion of treated patients had symptom resolution; however, the role of previous antimicrobials is unclear. One RCT comparing FMT with 2 control groups (n = 43) reported resolution of symptoms in 81%, 31%, and 23% of the FMT, vancomycin, or vancomycin-plus-bowel lavage groups, respectively (P < 0.001 for both control groups vs. FMT). An RCT comparing FMT route (n = 20) reported no difference between groups (60% in the nasogastric tube group and 80% in the colonoscopy group; P = 0.63). Across all studies for recurrent CDI, symptom resolution was seen in 85% of cases. In 7 case-series studies of patients with refractory CDI, symptom resolution ranged from 0% to 100%. Among 7 patients treated with FMT for initial CDI, results were mixed., Limitation: Most studies were uncontrolled case-series studies; only 2 RCTs were available for analysis., Conclusion: Fecal microbiota transplantation may have a substantial effect with few short-term adverse events for recurrent CDI. Evidence is insufficient on FMT for refractory or initial CDI treatment and on whether effects vary by donor, preparation, or delivery method., Primary Funding Source: U.S. Department of Veterans Affairs.
- Published
- 2015
- Full Text
- View/download PDF
18. Antimicrobial stewardship programs in inpatient hospital settings: a systematic review.
- Author
-
Wagner B, Filice GA, Drekonja D, Greer N, MacDonald R, Rutks I, Butler M, and Wilt TJ
- Subjects
- Hospitals statistics & numerical data, Humans, Infections drug therapy, Inpatients, Program Evaluation, Treatment Outcome, Anti-Infective Agents therapeutic use, Drug Utilization Review, Hospitals standards
- Abstract
Objective: Evaluate the evidence for effects of inpatient antimicrobial stewardship programs (ASPs) on patient, prescribing, and microbial outcomes., Design: Systematic review., Methods: Search of MEDLINE (2000 through November 2013), Cochrane Library, and reference lists of relevant studies. We included English language studies with patient populations relevant to the United States (ie, infectious conditions and prescriptions required for antimicrobials) that evaluated ASP interventions and reported outcomes of interest. Study characteristics and outcomes data were extracted and reviewed by investigators and trained research personnel., Results: Few intervention types (eg, audit and feedback, guideline implementation, and decision support) substantially impacted patient outcomes, including mortality, length of stay, readmission, or incidence of Clostridium difficile infection. However, most interventions were not powered adequately to demonstrate impacts on patient outcomes. Most interventions were associated with improved prescribing patterns as measured by decreased antimicrobial use or increased appropriate use. Where reported, ASPs were generally associated with improvements in microbial outcomes, including institutional resistance patterns or resistance in the study population. Few data were provided on harms, sustainability, or key intervention components. Studies were typically of short duration, low in methodological quality, and varied in study design, populations enrolled, hospital setting, ASP intent, intervention composition and implementation, comparison group, and outcomes assessed., Conclusions: Numerous studies suggest that ASPs can improve prescribing and microbial outcomes. Strength of evidence was low, and most studies were not designed adequately to detect improvements in mortality or other patient outcomes, but obvious adverse effects on patient outcomes were not reported.
- Published
- 2014
- Full Text
- View/download PDF
19. Tigecycline treatment for urinary tract infections: case report and literature review.
- Author
-
Drekonja DM and Johnson JR
- Subjects
- Drug Resistance, Multiple, Bacterial, Enterobacter isolation & purification, Enterobacteriaceae Infections microbiology, Humans, Male, Middle Aged, Minocycline therapeutic use, Prostatitis microbiology, Tigecycline, Treatment Outcome, Urinary Tract Infections microbiology, Anti-Bacterial Agents therapeutic use, Enterobacteriaceae Infections drug therapy, Minocycline analogs & derivatives, Prostatitis drug therapy, Urinary Tract Infections drug therapy
- Abstract
Antimicrobial resistance among Gram-negatives is increasing; treatment options are limited. Although tigecycline is used infrequently for urinary tract infection (UTI), greater use is likely as resistance increases. We report successful treatment of an episode of febrile UTI and probable prostatitis with tigecycline, and summarize the relevant literature.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.